Malaria has become one of the public health concerns. According to
the World Health Organization, the estimated cases of malaria in 2016
was 216 million globally, which was almost 2.5% higher than that of
2015. This mosquito-borne disease causes severe illness in children
and adults. Pregnant women and unborn children cannot escape from
aftermaths of malaria. It is reported that malaria-affected pregnant
women give premature birth or sometimes give birth to dead infants.
Various safety measures to curb malaria include the use of mosquito
nets, spraying of insecticides, or quinine. However, current studies
have concluded that a) mosquitos are resistant to insecticides, b)
insecticides have harmful effects to human beings, and c) malaria
becomes resistant to drugs. Therefore, steps to curb malaria
gradually decreases.
Report Overview @
https://www.transparencymarketresearch.com/malaria-vaccines-market.html
To combat this devastating scenario, the importance of malaria
vaccines grows worldwide. These vaccines may help to fill the gaps of
other malaria safety measures. The global malaria vaccines market is
driven by increasing incidence of malaria, growing awareness of the
aftermaths of the disease, and rising diagnosis and treatment rate
along with recommended number of doses of malaria vaccines. However,
in the next few years, the market is likely to face challenges such
as high price of vaccines, weak supply chain network in developing
countries, and stringent regulatory policies. On the other hand,
worldwide research and development, R&D investments, vaccination
programs, and technological breakthroughs are expected to open new
avenues for the growth of the market in the near future.
RTS,S/AS01 (Mosquirix™) is the most advanced candidate vaccine
found to combat the most lethal form of human malaria, Plasmodium
falciparum. A phase 3 clinical trial of RTS,S/AS01 began in May 2009.
After almost six years, the European Medicines Agency shared a
positive opinion of the vaccine.
The global malaria vaccines market has been segmented based on agent,
product, end-user, and region. In terms of agent, the market is
categorized into Plasmodium falciparum, Plasmodium vivax, and
Anopheles species. Based on product, the market is segmented into
reagents, assays, proteins, and antibodies. In terms of end-user, the
market is classified into hospitals, independent clinics, households,
and others (government established health camps and health centers).
Download Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37121
Geographically, the global malaria vaccines market is distributed
over North America, Europe, Asia Pacific, Latin America, and Middle
East & Africa. According to the WHO, more than 200 million
confirmed cases (90% of the global cases) of malaria were reported in
the Africa region in 2015. Additionally, limited financial resources,
low awareness about aftermaths of malaria, low diagnostic and
treatment rate, and weak distribution channels are the potential
factors which are likely to drive the MEA region to become a leading
contributor of the global market. Asia Pacific is also estimated to
be a potential market. According to a research, almost 1.2 million
confirmed cases of malaria and 550 deaths were reported in India in
the most recent times in 2015. The same study also warned that 95% of
India’s population live in malaria-endemic areas and about 13
million people in Bangladesh.
China which showed a high rate of
malaria cases in 1970, represented only 17,000 confirmed cases of
malaria in 2013. About 15 million confirmed cases of malaria were
reported in the Asia Pacific region in 2016, revealed by a separate
study. Most of the malaria cases in Latin America are found in the
Amazon region. A study published in the British Medical Journal, in
2017, reported that Brazil displayed an increasing rate of malaria
cases in recent years; the confirmed malaria cases in the country had
grown to nearly 25 cases per 1,000 population in 2015 from 14 cases
per 1,000 population in 2014. The North America and Europe regions
displayed a minimal number of malaria cases in 2016. Nevertheless,
visitors, students, and business delegates from developed countries
of these regions who travel to malaria endemic regions are suggested
to administer malaria vaccines.
Key players operating in the global market for malaria vaccines are
GlaxoSmithKline, Nobelpharma, GenVec, Inc., and Sanaria. Other
promising vendors are CellFree Sciences Co. Ltd., Cadila Healthcare
Ltd., VLP Therapeutics LLC, and Genome ReS Ltd.
Pre-Book Full Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=37121<ype=S
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA
- Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment